ENOblock

has antineoplastic activity; now disproven to be an enolase inhibitor; structure in first source

Also Known As:

AP-III-a4 compound; N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-4-((4-(cyclohexylmethyl)amino-6-((4-fluorophenyl)methyl)amino-1,3,5-triazin-2-yl)amino)benzeneacetamide

Networked: 7 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Jung, Da-Woon: 3 articles (01/2019 - 01/2013)
2.	Kim, Woong-Hee: 3 articles (01/2019 - 01/2013)
3.	Williams, Darren R: 3 articles (01/2019 - 01/2013)
4.	Banik, Naren L: 2 articles (10/2020 - 10/2017)
5.	Capone, Mollie: 2 articles (10/2020 - 10/2017)
6.	Haque, Azizul: 2 articles (10/2020 - 10/2017)
7.	Matzelle, Denise: 2 articles (10/2020 - 10/2017)
8.	Chang, Young-Tae: 2 articles (01/2019 - 01/2013)
9.	Cho, Haaglim: 2 articles (01/2019 - 01/2017)
10.	Lee, Ji-Hyung: 2 articles (01/2019 - 01/2017)

Related Diseases

1.	Obesity 01/01/2019 - "ENOblock inhibits the pathology of diet-induced obesity." 01/01/2019 - "Our results support the further drug development of ENOblock as a therapeutic for obesity and suggest enolase as a new target for this disorder."
2.	Inflammation (Inflammations) 01/01/2019 - "The mechanism of ENOblock was identified as transcriptional repression of master regulators of lipid homeostasis (Srebp-1a and Srebp-1c), gluconeogenesis (Pck-1) and inflammation (Tnf-α and Il-6). " 10/01/2020 - "Immunohistochemical analyses of inflammatory markers vimentin, Cox-2, and caspase-1 indicated that enolase inhibition attenuated the elevated levels of inflammation seen following SCI. Iba1, GFAP, NFP, and CSPG staining indicated that enolase inhibition with prolonged administration of ENOblock reduced microglia/astrocyte activation and lead to enhanced neuroprotection in SCI. An analysis of metabolic hormones revealed that ENOblock treatment significantly upregulated plasma concentrations of peptide YY, glucagon-like peptide 1, glucose-dependent insulinotropic peptide, glucagon, and insulin hormones as compared to vehicle-treated controls (Mann-Whitney, p ≤ 0.05). "
3.	Diabetes Complications 01/01/2017 - "Indicators of secondary diabetic complications, such as tissue apoptosis, inflammatory markers and fibrosis were inhibited by ENOblock treatment. "
4.	Neoplasms (Cancer) 01/01/2013 - "Further analysis revealed that ENOblock can inhibit cancer cell metastasis in vivo. " 01/01/2013 - "ENOblock was isolated by small molecule screening in a cancer cell assay to detect cytotoxic agents that function in hypoxic conditions, which has previously been shown to induce drug resistance. "
5.	Neoplasm Metastasis (Metastasis) 01/01/2013 - "Further analysis revealed that ENOblock can inhibit cancer cell metastasis in vivo. "

Related Drugs and Biologics

1.	Phosphopyruvate Hydratase (Enolase)
2.	Lipids
3.	Glucagon-Like Peptide 1 (GLP 1)
4.	Peptide YY
5.	Vimentin
6.	Insulin (Novolin)
7.	Hormones (Hormone)
8.	Glucagon (Glukagon)
9.	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)
10.	Cytotoxins (Cytolysins)